Browsing by Author "Matos, L"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
- Gravidez e Amamentação. Efeitos Secundários dos Fármacos Usados no Tratamento das Doenças da Tiróide, Sobre o Feto e o Recém-NascidoPublication . Matos, L; Afonso, AOs autores referem os efeitos secundários, sobre o feto e o recém-nascido, dos antitiroideus de síntese, dos bloqueadores ß, dos iodetos, do iodoradiactivo(131I), carbonato de lítio e tiroxina. Os fármacos mais frequentemente utilizados são os antitiroideus de síntese e a tiroxina. Os riscos dos antitiroideus estão relacionados com o facto de atravessarem a barreira placentar e poderem provocar bócio e hipotiroidismo fetais. As hormonas tiroideias maternas, que atravessam a placenta, são muito importantes para o normal desenvolvimento neuronal de feto durante o primeiro trimestre.
- Hipoparatiroidismo Crónico: Revisão de 5 Casos ClínicosPublication . Anselmo, J; Martins, J; Matos, L; Boavida, J; Carreiras, F; Correia, G; Lima e Silva, F; Pereira, E; Nunes Corrêa, JCEm 5 doentes com longa evolução clínica de tetania e/ou convulsões e com hipocalcemia e hiperfosfatemia documentadas, detectaram-se valores baixos ou inapropriados de paratormona. Apenas 2 doentes referiam história de tiroidectomia sub-total e todos apresentavam calcificação dos núcleos da base, cataratas subcapsulares bilaterais e prolongamento do intervalo QTc do ECG. Após 1 mês de terapêutica oral com cálcio e calcitriol os valores de calcemia e fosfatemia estavam próximos do normal, excepto num dos doentes em que essa normalização foi mais tardia, e só teve início após a correcção da magnesiemia. Ainda neste último doente a correlação estatística entre o intervalo QTc do ECG e a calcemia foi muito significativa (P<0,001) concluindo-se que o intervalo QTc pode ser um indicador útil e acessível em situações agudas de hipocalcemia sintomática.
- One Year of Lamivudine Therapy for Portuguese Patients with Chronic Hepatitis BPublication . Areias, J; Calinas, F; Porto, A; Carvalho, A; Freitas, D; Macedo, G; Noronha, R; Cotter, J; Meliço-Silvestre, A; Peixe, R; Pratas, J; Barrote, D; Teixeira, R; Augusto, F; Carrilho, I; Campante, F; Velosa, J; Carvalho, L; Duarte, MA; Guerreiro, H; Pires, C; Silva, A; Cotrim, I; Guedes, F; Tomé, L; Marcelino, M; Gonçalves, C; Ferreira, E; Matos, L; Peixe, P; Esteves, J; Valente, T; Simões, C; Marinho, C; Jasmins, L; Vieira, MJ; Marinho, R; Matos, P; Estevens, J; Carrasquinho, J; Salcedo, G; Parada, P; Teixeira, COBJECTIVE: To assess the efficacy of lamivudine treatment on hepatitis B e antigen (HBeAg) and/or hepatitis B surface antigen (HBsAg) seroconversion, on other virological and serological markers of response including hepatitis B virus (HBV) DNA and serum aminotransferases, and the safety of lamivudine treatment in hepatitis B patients. PATIENTS: This phase III open-label study evaluated the virological and biochemical response to lamivudine in 70 Portuguese patients with HBeAg positive chronic hepatitis B. Patients were treated with lamivudine 100mg once daily for 12 months. METHODS: Antiviral activity was assessed by measuring alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels at all protocol visits, and hepatitis B serology and HBV DNA were performed at baseline and at month 12 visits. Evaluation of safety and tolerance was based on clinical adverse events and laboratory analyses. RESULTS: The primary endpoint was virological response at month 12, defined as loss of detectable HBeAg from serum with a reduction of HBV DNA to undetectable levels, and this was observed in 19/69 (27.5%) of patients. Almost half of the patients were HBV DNA negative by this time. Mean ALT values decreased steadily during treatment and by 12 months 61% of patients had values within the normal range. HBeAg seroconversion (HBeAg negative, HBeAb positive) was achieved in 27.9% of patients by 12 months, although all patients remained HBsAg positive. CONCLUSION: Lamivudine was well tolerated and the incidence of adverse events was similar to those reported in previous studies. Lamivudine treatment resulted in virological and biochemical improvements in HBeAg positive chronic hepatitis B patients, with HBeAg seroconversion in one-third of patients.
- Tranexamic Acid for Major Spinal Surgery in Children. A Retrospective StudyPublication . Correia, C; Matos, L; Rocha, TIntroduction: Paediatric patients who undergo posterior spinal fusion surgery to correct scoliosis often require multiple blood transfusions. Tranexamic acid is a synthetic antifibrinolytic drug that reduces transfusion requirements in scoliosis surgery (1),(2),(3). Methods: To evaluate the efficacy of prophylactic tranexamic acid (TA) (initial dose of 10mg/kg and infusion of 1mg.kg(-1).h(-1)) in reducing perioperative blood transfusion requirements, we reviewed patients files and compared the amount of blood lost and blood transfused in the perioperative period of 12 patients (54.5%) that received TA and 10 patients (45.5%) who did not received TA. T-Student test was applied. Results: The average difference of blood losses (2,67 +/- 6,06ml) and blood transfused (212,9 +/- 101,1ml) between the two groups was not statistically significant (p>0.05). No thrombotic complications were detected in either group. Discussion: Results of the current study showed that prophylactic low dose of TA did not have a significant effect in the management of intraoperative blood loss and transfusion requirements in children undergoing scoliosis surgery. It is important to emphasize that our study is retrospective and that the size of the sample is small. Further studies are needed to evaluate the efficacy and safety of TA on paediatric scoliosis surgery.